Sellas jumps 17% after hours as Phase 3 AML trial results are due this month
Asianet Newsable · · AI-summarised by FinFlash
Sellas Life Sciences shares rose 17% in after-hours trading after the company said topline results from its Phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia are expected this month. The stock had fallen nearly 5% on Thursday to $8.03 but is up 113% year to date. Third-quarter net loss widened to A binary catalyst for SLS: the REGAL readout could drive a sharp move either way, with read-through for small-cap AML drug developers. Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.So What?
Understand the context